US2003171287A1PendingUtilityA1

Medicinal compositions for angiogenic therapy

45
Priority: Jun 27, 2000Filed: Jun 27, 2001Published: Sep 11, 2003
Est. expiryJun 27, 2020(expired)· nominal 20-yr term from priority
Inventors:Ryuichi MorishitaHiromi KoikeTadashi TanabeMotokuni Aoki
A61K 31/5585A61K 31/711A61K 48/00A61P 9/10A61K 38/1858A61K 38/1709A61K 38/52A61K 38/1833A61P 9/00
45
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides: (1) pharmaceutical compositions for angiogenic therapy which contain, as the active ingredients, at least one substance selected from substances having vasodilating effect and/or platelet aggregation inhibitory effect, and substances producing them; and a gene encoding an angiogenesis factor; (2) agents for potentiating the angiogenic effect of a gene encoding an angiogenesis factor that contain, as the active ingredient, at least one substance selected from substances having vasodilating effect and/or platelet aggregation inhibitory effect and substances producing them; (3) an angiogenic agent which contains a prostacyclin synthase gene as the active ingredient; (4) pharmaceutical compositions for angiogenic therapy which contain ets-1 gene and another gene encoding an angiogenesis factor as the active ingredients; (4) an agent which contain ets 1 gene as the active ingredient for potentiating the angiogenic effect of another gene encoding an angiogenesis factor; and (5) an angiogenic agent which contains ets-1 gene as the active ingredient.

Claims

exact text as granted — not AI-modified
1 . A pharmaceutical composition for angiogenic therapy which contains, as the active ingredients, at least one substance selected from the group of: substances having vasodilating effect and/or platelet aggregation inhibitory effect, and substances producing them; and a gene encoding an angiogenesis factor.  
     
     
         2 . A pharmaceutical composition for angiogenic therapy, which is characterized by the combined use of a gene encoding an angiogenesis factor with at least one substance selected from the group of: substances having vasodilating effect and/or platelet aggregation inhibitory effect, and substances producing them.  
     
     
         3 . The pharmaceutical composition for angiogenic therapy of  claim 1  or  2 , wherein the angiogenesis factor is HGF and/or VEGF.  
     
     
         4 . The pharmaceutical composition for angiogenic therapy of any one of  claims 1  to  3 , wherein the substance producing a substance having vasodilating effect and/or platelet aggregation inhibitory effect is in the form of a gene.  
     
     
         5 . The pharmaceutical composition for angiogenic therapy of  claim 4 , wherein the gene is prostacyclin synthase gene.  
     
     
         6 . A pharmaceutical composition for angiogenic therapy which contains HGF gene and prostacyclin synthase gene as the active ingredients.  
     
     
         7 . A pharmaceutical composition for angiogenic therapy which is characterized by the combined use of HGF gene and prostacyclin synthase gene.  
     
     
         8 . A pharmaceutical composition for angiogenic therapy which contains VEGF gene and prostacylin synthase gene as the active ingredients.  
     
     
         9 . A pharmaceutical composition for angiogenic therapy, which is characterized by the combined use of VEGF gene and prostacyclin synthase gene.  
     
     
         10 . The pharmaceutical composition for angiogenic therapy of any one of  claims 1  to  9 , wherein the composition is used for treating or preventing ischemic disease or arterial disease.  
     
     
         11 . The pharmaceutical composition for angiogenic therapy of  claim 10 , wherein the ischemic disease or arterial disease is selected from the group of arteriosclerosis obliterans, myocardial infarction, angina pectoris, cardiomyopathy, and cerebrovascular disease.  
     
     
         12 . The pharmaceutical composition for angiogenic therapy of any one of  claims 1  to  11 , wherein the gene is introduced in the form of naked DNA.  
     
     
         13 . An agent for potentiating the angiogenic effect due to a gene encoding an angiogenesis factor which contains, as the active ingredient, at least one substance selected from the group of: substances having vasodilating effect and/or platelet aggregation inhibitory effect, and substances producing them.  
     
     
         14 . The agent for potentiating the angiogenic effect of  claim 13 , wherein the angiogenesis factor is HGF and/or VEGF.  
     
     
         15 . The agent for potentiating the angiogenic effect of  claim 13  or  14 , which contains prostacyclin synthase gene as the active ingredient.  
     
     
         16 . An agent for potentiating the angiogenic effect due to HGF gene which contains prostacyclin synthase gene as the active ingredient.  
     
     
         17 . The agent for potentiating the angiogenic effect of any one of  claims 13  to  16 , wherein the agent is used for treating or preventing ischemic disease or arterial disease.  
     
     
         18 . An angiogenic agent which contains prostacyclin synthase gene as the active ingredient.  
     
     
         19 . The angiogenic agent of  claim 18 , wherein the agent is used for treating or preventing ischemic disease or arterial disease.  
     
     
         20 . A pharmaceutical composition for angiogenic therapy which contains ets-1 gene and another gene encoding an angiogenesis factor as the active ingredients.  
     
     
         21 . A pharmaceutical composition for angiogenic therapy, which is characterized by the combined use of ets-1 gene and another gene encoding an angiogenesis factor.  
     
     
         22 . The pharmaceutical composition for angiogenic therapy of  claim 20  or  21 , wherein the angiogenesis factor is HGF and/or VEGF.  
     
     
         23 . A pharmaceutical composition for angiogenic therapy which contains HGF gene and ets-1 gene as the active ingredients.  
     
     
         24 . A pharmaceutical composition for angiogenic therapy, which is characterized by the combined use of HGF gene and ets-1 gene.  
     
     
         25 . The pharmaceutical composition for angiogenic therapy of any one of  claims 20  to  24 , wherein the composition is used for treating or preventing ischemic disease or arterial disease.  
     
     
         26 . An agent containing ets-1 gene as the active ingredient that potentiates the angiogenic effect due to another gene encoding an angiogenesis factor.  
     
     
         27 . The agent for potentiating the angiogenic effect of  claim 26 , wherein the angiogenesis factor is HGF and/or VEGF.  
     
     
         28 . An agent for potentiating the angiogenic effect due to HGF gene, which contains ets-1 gene as the active ingredient.  
     
     
         29 . The agent for potentiating the angiogenic effect of any one of claims  26 . to  28 , wherein the agent is used for treating or preventing ischemic disease or arterial disease.  
     
     
         30 . An angiogenic agent which contains ets-1 gene as the active ingredient.  
     
     
         31 . The angiogenic agent of  claim 30  which is used for treating or preventing ischemic disease or arterial disease.

Join the waitlist — get patent alerts

Track US2003171287A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.